Breakthrough Treatment for Patients with Barrett’s Esophagus Now Available at Franklin Medical Center
Radiofrequency ablation system reduces risk of Barrett’s esophagus progressing to esophageal cancer1
Winnsboro, Louisiana – November 2, 2017 – Dr. David Gutierrez now offers the Barrx™ radiofrequency ablation system at Franklin Medical Center. This treatment removes esophageal tissues affected by Barrett’s esophagus, a pre-cancerous disease (dysplastic Barrett’s esophagus). Franklin Medical Center is the only facility in North Louisiana, outside of Shreveport, that offers radiofrequency ablation.
Over 12.5 million people in the U.S. have Barrett’s esophagus, many of whom are not even diagnosed.2 Barrett’s esophagus occurs when cells in the lower esophagus are affected by chronic exposure to acid. Because of its strong association with esophageal cancer, Barrett’s esophagus is considered a pre-cancerous disease.
The Barrx™ radiofrequency ablation system uses heat to remove tissue affected by Barrett’s esophagus. In a clinical study, the Barrx™ radiofrequency ablation system was found to reduce the risk of Barrett’s esophagus progressing to esophageal cancer by over 90%.2,3
If you have undergone treatment or observation for gastroesophageal reflux disease (GERD), chronic heartburn or other acid reflux-related symptoms, you may be at risk of developing Barrett’s esophagus. Early detection of Barrett’s esophagus may reduce the risk of this disease progressing to esophageal cancer.
Contact Dr. David Gutierrez at Franklin Medical Center (318-435-4084) to schedule a consultation and see if the Barrx™ radiofrequency ablation system is appropriate for you.
Dr. David Gutierrez
2104 Loop Road
Winnsboro, LA 71295
- Dymedex Market Development Consulting, Strategic Market Assessment: Barrx–GI, October 30, 2014.
- Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277-88.
- Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs. endoscopic surveillance for patients with Barrett’s esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311:1209-17.